Willdan Group, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Willdan Group, Inc. on February 22, 2007, covering events occurring on February 20, 2007. The filing addresses the departure of a senior executive and the execution of a related compensatory agreement.
Key Financial Metrics
The filing does not provide general financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific severance package for the departing executive:
- Lump-sum payment: $16,155 (representing one month's base salary), paid on February 6, 2007.
- Wage continuation: $192,515 payable over eleven months following February 6, 2007.
- Benefits: Continued medical, dental, and vision insurance during the wage continuation period.
- Asset transfer: Title to the Company automobile currently in the executive's possession.
Material Changes
The primary material change reported is the departure of Richard Kopecky, Senior Vice President of Willdan Group, Inc. and President and Chief Executive Officer of its subsidiary, Willdan. His departure as an executive officer was effective February 6, 2007. An agreement and general release were executed on February 20, 2007, formalizing the separation terms.
Outlook, Risks, and Unusual Items
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general business risks. The unusual item is the executive departure and the associated compensatory arrangement, which includes a release of claims against the Company and mutual non-disparagement provisions.
Investor Verification Checklist
- Confirm the effective date of Richard Kopecky's departure (February 6, 2007).
- Verify the total cash compensation obligation ($208,670) and the payment schedule.
- Review the attached Exhibit 10.1 (Agreement and General Release) for specific conditions regarding the release of claims and non-disparagement.
- Check subsequent filings for the appointment of a successor to Mr. Kopecky's roles.